NVCR
NovoCure Ltd.
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$14.90
+10.95%Year over year
Reported trailing growth
- Revenue
- +12.9%
- EBITDA
- -9.2%
- EBIT
- +29.5%
- EPS
- +34.2%
- Free cash flow
- +68.9%
- Operating cash flow
- +110.4%
Forward estimates
Based on analyst estimates
- Revenue
- +8.0%
- EBITDA
- +45.4%
- EPS
- +29.8%
Three-year CAGR
- Revenue
- +6.8%
- EBITDA
- -11.0%
- EBIT
- +9.8%
- Net income
- +19.2%
- EPS
- +21.8%
- Free cash flow
- -9.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026